Immunology market trends reveal rising evidence standards as psoriasis treatment advances, deeper remission strategies in inflammatory bowel disease, emerging TL1A and IL-1 therapies, and indication-expansion challenges reshape clinical differentiation and biopharma competition.

Coverage Period: September 22 – October 26, 2026

Introduction

Recent immunology developments highlighted a growing competitive tension: approved therapies are building stronger evidence for deep and durable disease control, while emerging treatments must demonstrate advantages against increasingly established standards.

Across psoriasis, inflammatory bowel disease (IBD), and other immune-mediated conditions, the reporting period brought comparative efficacy results, long-term evidence for marketed therapies, progress in emerging mechanisms, and a notable late-stage clinical failure.

The central strategic question is how these developments are changing expectations for new treatments—and how established therapies may defend their positions as the pipeline evolves.

Companies covered: Johnson & Johnson / Janssen, AbbVie, Takeda, Merck / MSD, Zenas BioPharma, argenx

Diseases covered: Crohn’s disease, Ulcerative colitis, IBD, Vitiligo, Psoriasis, Sjögren’s disease

Watch the summary video

Executive Summary: Key Strategic Developments in Immunology

• The competitive benchmark is becoming more demanding. Long-term evidence for approved therapies is strengthening existing treatment positions, while head-to-head data are showing where next-generation assets could offer meaningful advantages. This creates a moving benchmark for pipeline development.
• Deeper disease control is gaining importance in IBD. Recent evidence supporting disease clearance and sustained clinical and endoscopic remission may influence future treatment goals, evidence-generation priorities, and competitive differentiation.
• Emerging mechanisms offer opportunities, but novelty is insufficient. Progress in TL1A and dual IL-1 inhibition supports diversification of the immunology pipeline. However, their market potential will depend on meaningful clinical advantages over established options.
• Platform expansion offers growth but carries indication-specific risk. Longer-term evidence and combination strategies may create new opportunities for existing therapies, while the failure of a late-stage Sjögren’s disease program underscores the difficulty of translating established mechanisms across diseases.

Strategic Perspective on Immunology Market Trends and Competitive Shifts

Psoriasis Treatment and Established Immunology Therapies Raise the Bar for Pipeline Innovation

One of October’s most important competitive signals comes from the relationship between approved treatments and investigational assets.

Established therapies are continuing to build their clinical evidence base beyond the studies that supported initial approval. Three-year guselkumab results in Crohn’s disease and longer-term upadacitinib data in vitiligo illustrate how additional evidence can strengthen treatment positioning and reinforce confidence in sustained outcomes.

Meanwhile, investigational therapies are being evaluated against increasingly demanding expectations. Takeda’s head-to-head results for zasocitinib demonstrated that next-generation oral TYK2 inhibition could challenge the efficacy positioning of an established oral psoriasis treatment.

These developments highlight an important dynamic: pipeline innovation is competing against a standard of care that continues to evolve.

For manufacturers developing new immunology assets, this raises the importance of differentiation strategies established early in clinical development. Demonstrating activity against placebo may support regulatory progress, but comparative efficacy, durability, safety, convenience, and patient-relevant benefits may ultimately determine commercial competitiveness.

For established manufacturers, continued evidence generation can help defend market positions even as new mechanisms approach commercialization.

Key Uncertainty: Stronger clinical evidence does not automatically translate into greater market share. Treatment sequencing, safety, reimbursement, and physician preferences will remain important in determining which advantages have commercial value.

Inflammatory Bowel Disease Treatment: Deep Remission and Disease Clearance

The clinical ambition of IBD treatment appears to be evolving from controlling symptoms toward achieving sustained control of underlying inflammation and potentially reducing future complications.

The VERDICT study provides an important signal by demonstrating that targeting disease clearance with vedolizumab was associated with fewer ulcerative colitis-related complications than targeting symptomatic remission alone among patients achieving their assigned targets.

Meanwhile, long-term guselkumab findings in Crohn’s disease reinforce the relevance of maintaining clinical and endoscopic remission over several years.

These findings address different questions, but both strengthen the evidence base for more ambitious treatment goals.

For the immunology market, the implications extend beyond the therapies involved. If deeper remission becomes a more widely adopted clinical objective, pipeline assets may face growing pressure to demonstrate objective disease control and durability rather than relying predominantly on short-term symptomatic endpoints.

This could also influence medical affairs strategies, future trial designs, and the evidence considered relevant by clinicians and payers.

Key Uncertainty: The feasibility and incremental clinical value of pursuing intensive treatment targets across broader patient populations remain to be established. Cost, monitoring requirements, and real-world implementation may affect adoption.

TL1A and IL-1 Inhibitors Expand Immunology Drug Development

The development of therapies targeting additional inflammatory pathways remains an important source of potential future competition.

October’s data provided further support for two approaches: TL1A inhibition in IBD and dual IL-1α/IL-1β inhibition in hidradenitis suppurativa.

Longer-term duvakitug findings supported continued development of TL1A inhibition, while exploratory biomarker results raised interest in possible effects on tissue remodeling. Positive Phase 3 lutikizumab results demonstrated the clinical potential of simultaneously targeting IL-1α and IL-1β in hidradenitis suppurativa, including effects on pain and flares.

The strategic significance lies less in adding new mechanisms to the pipeline than in the possibility of addressing outcomes or patient needs not fully met by existing therapies.

For developers, differentiated mechanisms may create opportunities in difficult-to-treat populations, support combination strategies, or broaden treatment choices.

However, the growing number of therapeutic approaches also raises the standard for meaningful differentiation. As established therapies accumulate durability data, new assets will need evidence that clearly supports their position in treatment pathways.

Key Uncertainty: The clinical relevance of potential antifibrotic effects from TL1A inhibition remains unproven, while the longer-term competitive positioning of dual IL-1 inhibition requires further evidence. Positive early or pivotal results do not establish superiority over available therapies.

Immunology Drug Development: Lifecycle Expansion and Clinical Risk

Expanding established immunology platforms into additional indications remains an important development strategy, but October’s evidence highlighted the uneven nature of that opportunity.

Long-term upadacitinib results in vitiligo support continued development of systemic treatment approaches, while exploratory findings combining the therapy with phototherapy suggest another potential direction for optimizing treatment.

Such approaches may allow manufacturers to extend the clinical relevance of existing assets and investigate complementary treatment strategies without relying exclusively on new molecular entities.

The discontinuation of argenx’s Phase 3 efgartigimod study in Sjögren’s disease presents the contrasting risk. An established therapeutic mechanism does not guarantee success when applied to a disease with different biological complexity and clinical characteristics.

This distinction matters for pipeline allocation and business development decisions. Platform experience may reduce some development uncertainties, but new indications still require strong disease-specific rationale, appropriate clinical endpoints, and patient-selection strategies.

Key Uncertainty: Exploratory combination benefits require confirmation, while the underlying reasons for the Sjögren’s study failure need further investigation. The ability to identify responsive patient populations remains a critical challenge.

What to Watch Next in the Immunology Treatment Landscape

Commercial positioning of next-generation TYK2 inhibitors: Regulatory decisions and subsequent treatment positioning will help establish whether superior oral psoriasis efficacy can translate into a meaningful competitive advantage.

Clinical validation of emerging IBD mechanisms: Duvakitug’s Phase 3 program will test whether TL1A inhibition can deliver sufficiently differentiated outcomes against an advancing treatment landscape.

Evolution of deep-remission strategies: Further evidence and real-world adoption of disease-clearance approaches will indicate whether IBD treatment expectations are changing in clinical practice.

Longer-term differentiation in hidradenitis suppurativa: Additional lutikizumab results and combination research may clarify the value of targeting complementary inflammatory pathways.

More selective immunology platform expansion: Follow-up research in vitiligo and Sjögren’s disease may offer insights into patient selection, combination strategies, and the limits of cross-indication development.

Key Takeaway: Clinical Evidence and Differentiation Shape Immunology Competition

October’s central immunology signal is the interaction between two forces: established therapies strengthening their evidence base and pipeline assets seeking to establish meaningful differentiation.

As approved treatments demonstrate deeper and more durable outcomes, the standard against which emerging therapies must compete may continue to rise. New mechanisms remain important, but their commercial potential will depend on the clinical advantages they can demonstrate within an evolving treatment landscape.

For biopharma companies, understanding this relationship between current standards of care and future pipeline competition will be increasingly important for clinical development, portfolio prioritization, and commercial strategy.

🌐 Explore LucidQuest Strategic Roundups across multiple therapy areas for deeper healthcare and pharma analysis

About LucidQuest

LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.

Learn more: www.lqventures.com

Contact us at: info@lqventures.com